Skip to main content
Erschienen in: Clinical Research in Cardiology 3/2010

01.03.2010 | Original Paper

Treatment of small coronary arteries with a paclitaxel-coated balloon catheter

verfasst von: Martin Unverdorben, Franz X. Kleber, Hubertus Heuer, Hans-Reiner Figulla, Christian Vallbracht, Matthias Leschke, Bodo Cremers, Stefan Hardt, Michael Buerke, Hanns Ackermann, Michael Boxberger, Ralf Degenhardt, Bruno Scheller

Erschienen in: Clinical Research in Cardiology | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

Treatment of lesions in small coronary arteries by percutaneous transluminal coronary intervention is limited by a high recurrence rate. We assessed the use of a paclitaxel-coated balloon in this indication.

Methods

One-hundred eighteen patients with stenoses in small coronary vessels were treated by a paclitaxel-coated balloon (3 μg/mm2). The main inclusion criteria encompassed diameter stenosis of ≥70% and ≤22 mm in length with a vessel diameter of 2.25–2.8 mm. Follow-up angiography was performed at scheduled 6-month post-intervention or whenever driven by clinical or electrocardiographic signs of ischemia. The primary endpoint was angiographic in-segment late lumen loss.

Results

Eighty-two of 118 patients (70%) with a vessel diameter of 2.35 ± 0.19 mm were treated with the drug-coated balloon only, while 32 patients required additional stent deployment. The mean in-segment late lumen loss was 0.28 ± 0.53 mm. In patients treated with the drug-coated balloon only, the in-segment late lumen loss was 0.16 ± 0.38 mm. At 12 months, the rate of major adverse cardiac events was 15% which was primarily due to the need for target lesion revascularization in 14 patients (12%). In those with additional bare metal stent implantation geographical mismatch between coated-balloon dilatation and stent implantation was significantly associated with the occurrence of restenosis.

Conclusion

Treatment of coronary stenosis in small coronary vessels with the paclitaxel-coated balloon was well tolerated. It may offer an alternative to the implantation of a drug-eluting stent (ClinicalTrials.gov Identifier: NCT00404144).
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Moreno R, Fernández C, Alfonso F, Hernández R, Pérez-Vizcayno MJ, Escaned J, Sabaté M, Bañuelos C, Angiolillo DJ, Azcona L, Macaya C (2004) Coronary stenting versus balloon angioplasty in small vessels: a meta-analysis from 11 randomized studies. J Am Coll Cardiol 43:1964–1972CrossRefPubMed Moreno R, Fernández C, Alfonso F, Hernández R, Pérez-Vizcayno MJ, Escaned J, Sabaté M, Bañuelos C, Angiolillo DJ, Azcona L, Macaya C (2004) Coronary stenting versus balloon angioplasty in small vessels: a meta-analysis from 11 randomized studies. J Am Coll Cardiol 43:1964–1972CrossRefPubMed
2.
Zurück zum Zitat Agostoni P, Biondi-Zoccai GG, Gasparini GL, Anselmi M, Morando G, Turri M, Abbate A, McFadden EP, Vassanelli C, Zardini P, Colombo A, Serruys PW (2005) Is bare-metal stenting superior to balloon angioplasty for small vessel coronary artery disease? Evidence from a meta-analysis of randomized trials. Eur Heart J 26:881–889CrossRefPubMed Agostoni P, Biondi-Zoccai GG, Gasparini GL, Anselmi M, Morando G, Turri M, Abbate A, McFadden EP, Vassanelli C, Zardini P, Colombo A, Serruys PW (2005) Is bare-metal stenting superior to balloon angioplasty for small vessel coronary artery disease? Evidence from a meta-analysis of randomized trials. Eur Heart J 26:881–889CrossRefPubMed
3.
Zurück zum Zitat Hausleiter J, Kastrati A, Mehilli J, Schühlen H, Pache J, Dotzer F, Dirschinger J, Schömig A (2002) Predictive factors for early cardiac events and angiographic restenosis after coronary stent placement in small coronary arteries. J Am Coll Cardiol 40:882–889CrossRefPubMed Hausleiter J, Kastrati A, Mehilli J, Schühlen H, Pache J, Dotzer F, Dirschinger J, Schömig A (2002) Predictive factors for early cardiac events and angiographic restenosis after coronary stent placement in small coronary arteries. J Am Coll Cardiol 40:882–889CrossRefPubMed
4.
Zurück zum Zitat Waksman R (1999) Late thrombosis after radiation. Sitting on a time bomb. Circulation 100:780–782PubMed Waksman R (1999) Late thrombosis after radiation. Sitting on a time bomb. Circulation 100:780–782PubMed
5.
Zurück zum Zitat Verin V, Popowski Y, de Bruyne B, Baumgart D, Sauerwein W, Lins M, Kovacs G, Thomas M, Calman F, Disco C, Serruys PW, Wijns W, Dose-Finding Study Group (2001) Endoluminal beta-radiation therapy for the prevention of coronary restenosis after balloon angioplasty. The Dose-Finding Study Group. N Engl J Med 344:243–249CrossRefPubMed Verin V, Popowski Y, de Bruyne B, Baumgart D, Sauerwein W, Lins M, Kovacs G, Thomas M, Calman F, Disco C, Serruys PW, Wijns W, Dose-Finding Study Group (2001) Endoluminal beta-radiation therapy for the prevention of coronary restenosis after balloon angioplasty. The Dose-Finding Study Group. N Engl J Med 344:243–249CrossRefPubMed
6.
Zurück zum Zitat Brunner-La Rocca HP, Kaiser C, Pfisterer M (2007) BASKET Investigators. Targeted stent use in clinical practice based on evidence from the Basel Stent Cost Effectiveness Trial (BASKET). Eur Heart J 28:719–725CrossRefPubMed Brunner-La Rocca HP, Kaiser C, Pfisterer M (2007) BASKET Investigators. Targeted stent use in clinical practice based on evidence from the Basel Stent Cost Effectiveness Trial (BASKET). Eur Heart J 28:719–725CrossRefPubMed
7.
Zurück zum Zitat Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R (2006) Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48:193–202CrossRefPubMed Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R (2006) Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48:193–202CrossRefPubMed
8.
Zurück zum Zitat Carlsson J, von Wagenheim B, Linder R, Anwari TM, Qvist J, Petersson I, Magounakis T, Lagerqvist B (2007) Is late stent thrombosis in drug-eluting stents a real clinical issue? A single-center experience and review of the literature. Clin Res Cardiol 96:86–93CrossRefPubMed Carlsson J, von Wagenheim B, Linder R, Anwari TM, Qvist J, Petersson I, Magounakis T, Lagerqvist B (2007) Is late stent thrombosis in drug-eluting stents a real clinical issue? A single-center experience and review of the literature. Clin Res Cardiol 96:86–93CrossRefPubMed
9.
Zurück zum Zitat Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Böhm M, Speck U (2006) Treatment of in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med 355:2113–2124CrossRefPubMed Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Böhm M, Speck U (2006) Treatment of in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med 355:2113–2124CrossRefPubMed
10.
Zurück zum Zitat Tepe G, Zeller T, Albrecht T, Heller S, Schwarzwälder U, Beregi JP, Claussen CD, Oldenburg A, Scheller B, Speck U (2008) Local taxane with short exposure for reduction of restenosis in distal arteries: THUNDER trial. N Engl J Med 358:689–699CrossRefPubMed Tepe G, Zeller T, Albrecht T, Heller S, Schwarzwälder U, Beregi JP, Claussen CD, Oldenburg A, Scheller B, Speck U (2008) Local taxane with short exposure for reduction of restenosis in distal arteries: THUNDER trial. N Engl J Med 358:689–699CrossRefPubMed
11.
Zurück zum Zitat Cutlip DE, Windecker S, Mehran R et al (2007) Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115:2344–2351CrossRefPubMed Cutlip DE, Windecker S, Mehran R et al (2007) Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115:2344–2351CrossRefPubMed
12.
Zurück zum Zitat ICH Harmonized Tripartite Guideline (1994) Clinical safety data management: definitions and standards for expedited reporting E2A. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use, October 1994. Available at: http://www.ich.org/LOB/media/MEDIA436.pdf. Accessed 23 Jun 2006 ICH Harmonized Tripartite Guideline (1994) Clinical safety data management: definitions and standards for expedited reporting E2A. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use, October 1994. Available at: http://​www.​ich.​org/​LOB/​media/​MEDIA436.​pdf. Accessed 23 Jun 2006
13.
Zurück zum Zitat Park SW, Lee CW, Hong MK, Kim JJ, Cho GY, Nah DY, Park SJ (2000) Randomized comparison of coronary stenting with optimal balloon angioplasty for treatment of lesions in small coronary arteries. Eur Heart J 21:1785–1789CrossRefPubMed Park SW, Lee CW, Hong MK, Kim JJ, Cho GY, Nah DY, Park SJ (2000) Randomized comparison of coronary stenting with optimal balloon angioplasty for treatment of lesions in small coronary arteries. Eur Heart J 21:1785–1789CrossRefPubMed
14.
Zurück zum Zitat Kastrati A, Schömig A, Dirschinger J, Mehilli J, Dotzer F, von Welser N, Neumann FJ (2000) A randomized trial comparing stenting with balloon angioplasty in small vessels in patients with symptomatic coronary artery disease. ISAR-SMART Study Investigators. Intracoronary Stenting or Angioplasty for Restenosis Reduction in Small Arteries. Circulation 102:2593–2598PubMed Kastrati A, Schömig A, Dirschinger J, Mehilli J, Dotzer F, von Welser N, Neumann FJ (2000) A randomized trial comparing stenting with balloon angioplasty in small vessels in patients with symptomatic coronary artery disease. ISAR-SMART Study Investigators. Intracoronary Stenting or Angioplasty for Restenosis Reduction in Small Arteries. Circulation 102:2593–2598PubMed
15.
Zurück zum Zitat Koning R, Chan C, Eltchaninoff H, Tron C, Janorkar S, Gupta V, Cribier A (1998) Primary stenting of de novo lesions in small coronary arteries: a prospective, pilot study. Cathet Cardiovasc Diagn 45:235–238CrossRefPubMed Koning R, Chan C, Eltchaninoff H, Tron C, Janorkar S, Gupta V, Cribier A (1998) Primary stenting of de novo lesions in small coronary arteries: a prospective, pilot study. Cathet Cardiovasc Diagn 45:235–238CrossRefPubMed
16.
Zurück zum Zitat Hausleiter J, Kastrati A, Mehilli J, Schühlen H, Pache J, Dotzer F, Glatthor C, Siebert S, Dirschinger J, Schömig A (2004) ISAR-SMART-2 Investigators. A randomized trial comparing phosphorylcholine-coated stenting with balloon angioplasty as well as abciximab with placebo for restenosis reduction in small coronary arteries. J Intern Med 256:388–397CrossRefPubMed Hausleiter J, Kastrati A, Mehilli J, Schühlen H, Pache J, Dotzer F, Glatthor C, Siebert S, Dirschinger J, Schömig A (2004) ISAR-SMART-2 Investigators. A randomized trial comparing phosphorylcholine-coated stenting with balloon angioplasty as well as abciximab with placebo for restenosis reduction in small coronary arteries. J Intern Med 256:388–397CrossRefPubMed
17.
Zurück zum Zitat Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, Breithardt G (2003) Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 362:1093–1099CrossRefPubMed Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, Breithardt G (2003) Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 362:1093–1099CrossRefPubMed
18.
Zurück zum Zitat Ardissino D, Cavallini C, Bramucci E, Indolfi C, Marzocchi A, Manari A, Angeloni G, Carosio G, Bonizzoni E, Colusso S, Repetto M, Merlini PA (2004) SES-SMART Investigators. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA 292:2727–2734CrossRefPubMed Ardissino D, Cavallini C, Bramucci E, Indolfi C, Marzocchi A, Manari A, Angeloni G, Carosio G, Bonizzoni E, Colusso S, Repetto M, Merlini PA (2004) SES-SMART Investigators. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA 292:2727–2734CrossRefPubMed
19.
Zurück zum Zitat Mehilli J, Dibra A, Kastrati A, Pache J, Dirschinger J, Schömig A (2006) Intracoronary Drug-Eluting Stenting to Abrogate Restenosis in Small Arteries (ISAR-SMART 3) Study Investigators. Eur Heart J 27:260–266CrossRefPubMed Mehilli J, Dibra A, Kastrati A, Pache J, Dirschinger J, Schömig A (2006) Intracoronary Drug-Eluting Stenting to Abrogate Restenosis in Small Arteries (ISAR-SMART 3) Study Investigators. Eur Heart J 27:260–266CrossRefPubMed
20.
Zurück zum Zitat Morice MC, Colombo A, Meier B, Serruys P, Tamburino C, Guagliumi G, Sousa E, Stoll HP, REALITY Trial Investigators (2006) Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA 295:895–904CrossRefPubMed Morice MC, Colombo A, Meier B, Serruys P, Tamburino C, Guagliumi G, Sousa E, Stoll HP, REALITY Trial Investigators (2006) Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA 295:895–904CrossRefPubMed
21.
Zurück zum Zitat Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, O’Shaughnessy CD, DeMaio S, Hall P, Popma JP, Koglin J, Russell ME, for the TAXUS V Investigators (2005) Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease. A randomized controlled trial. JAMA 294:1215–1223CrossRefPubMed Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, O’Shaughnessy CD, DeMaio S, Hall P, Popma JP, Koglin J, Russell ME, for the TAXUS V Investigators (2005) Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease. A randomized controlled trial. JAMA 294:1215–1223CrossRefPubMed
22.
Zurück zum Zitat Elezi S, Dibra A, Mehilli J, Pache J, Wessely R, Schömig A, Kastrati A (2006) Vessel size and outcome after coronary drug-eluting stent placement: results from a large cohort of patients treated with sirolimus- or paclitaxel-eluting stents. J Am Coll Cardiol 48:1304–1309CrossRefPubMed Elezi S, Dibra A, Mehilli J, Pache J, Wessely R, Schömig A, Kastrati A (2006) Vessel size and outcome after coronary drug-eluting stent placement: results from a large cohort of patients treated with sirolimus- or paclitaxel-eluting stents. J Am Coll Cardiol 48:1304–1309CrossRefPubMed
23.
Zurück zum Zitat Tanimoto S, Daemen J, Tsuchida K, García-García HM, de Jaegere P, van Domburg RT, Serruys PW (2007) Two-year clinical outcome after coronary stenting of small vessels using 2.25-mm sirolimus- and paclitaxel-eluting stents: insight into the RESEARCH and T-SEARCH registries. Catheter Cardiovasc Interv 69(1):94–103CrossRefPubMed Tanimoto S, Daemen J, Tsuchida K, García-García HM, de Jaegere P, van Domburg RT, Serruys PW (2007) Two-year clinical outcome after coronary stenting of small vessels using 2.25-mm sirolimus- and paclitaxel-eluting stents: insight into the RESEARCH and T-SEARCH registries. Catheter Cardiovasc Interv 69(1):94–103CrossRefPubMed
24.
Zurück zum Zitat Scheller B, Speck U, Abramjuk C, Bernhardt U, Böhm M, Nickenig G (2004) Paclitaxel balloon coating—a novel method for prevention and therapy of restenosis. Circulation 110:810–814CrossRefPubMed Scheller B, Speck U, Abramjuk C, Bernhardt U, Böhm M, Nickenig G (2004) Paclitaxel balloon coating—a novel method for prevention and therapy of restenosis. Circulation 110:810–814CrossRefPubMed
25.
Zurück zum Zitat Speck U, Scheller B, Abramjuk C, Breitwieser C, Dobberstein J, Böhm M, Hamm B (2006) Neointima inhibition: comparison of effectiveness of non-stent-based local drug delivery and a drug-eluting stent in porcine coronary arteries. Radiology 240:411–418CrossRefPubMed Speck U, Scheller B, Abramjuk C, Breitwieser C, Dobberstein J, Böhm M, Hamm B (2006) Neointima inhibition: comparison of effectiveness of non-stent-based local drug delivery and a drug-eluting stent in porcine coronary arteries. Radiology 240:411–418CrossRefPubMed
26.
Zurück zum Zitat Cremers C, Speck U, Kaufels N, Mahnkopf D, Kühler M, Böhm M (2009) Scheller B: drug-eluting balloon: very short-term exposure and overlapping. Thromb Haemost 101:201–206PubMed Cremers C, Speck U, Kaufels N, Mahnkopf D, Kühler M, Böhm M (2009) Scheller B: drug-eluting balloon: very short-term exposure and overlapping. Thromb Haemost 101:201–206PubMed
27.
Zurück zum Zitat Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Böhm M, Speck U (2008) Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. Clin Res Cardiol 97:773–781CrossRefPubMed Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Böhm M, Speck U (2008) Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. Clin Res Cardiol 97:773–781CrossRefPubMed
28.
Zurück zum Zitat Unverdorben M, Vallbracht C, Heuer H, Hengstenberg C, Maikowski C, Werner GS, Antoni D, Kleber FX, Bocksch W, Leschke M, Ackermann H, Boxberger M, Speck U, Degenhardt R, Scheller B (2009) Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation 119:2986–2994CrossRefPubMed Unverdorben M, Vallbracht C, Heuer H, Hengstenberg C, Maikowski C, Werner GS, Antoni D, Kleber FX, Bocksch W, Leschke M, Ackermann H, Boxberger M, Speck U, Degenhardt R, Scheller B (2009) Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation 119:2986–2994CrossRefPubMed
29.
Zurück zum Zitat Werk M, Langner S, Reinkensmeier B, Boettcher HF, Tepe G, Dietz U, Hosten N, Hamm B, Speck U, Ricke J (2008) Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon—FemPac randomized pilot trial. Circulation 118:1358–1365CrossRefPubMed Werk M, Langner S, Reinkensmeier B, Boettcher HF, Tepe G, Dietz U, Hosten N, Hamm B, Speck U, Ricke J (2008) Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon—FemPac randomized pilot trial. Circulation 118:1358–1365CrossRefPubMed
30.
Zurück zum Zitat Scheller B, Speck U, Böhm M (2007) Prevention of restenosis—is angioplasty the answer? Heart 93:539–541CrossRefPubMed Scheller B, Speck U, Böhm M (2007) Prevention of restenosis—is angioplasty the answer? Heart 93:539–541CrossRefPubMed
31.
Zurück zum Zitat Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, Valsecchi O, Kolodgie FD (2004) Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 109:701–705CrossRefPubMed Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, Valsecchi O, Kolodgie FD (2004) Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 109:701–705CrossRefPubMed
32.
Zurück zum Zitat King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, Jacobs AK, Morrison DA, Williams DO, WRITING COMMITTEE MEMBERS, Feldman TE, Kern MJ, O’Neill WW, Schaff HV, Whitlow PL, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW (2008) 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation 117:261–295CrossRefPubMed King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, Jacobs AK, Morrison DA, Williams DO, WRITING COMMITTEE MEMBERS, Feldman TE, Kern MJ, O’Neill WW, Schaff HV, Whitlow PL, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW (2008) 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation 117:261–295CrossRefPubMed
33.
Zurück zum Zitat Herdeg C, Göhring-Frischholz K, Haase KK, Geisler T, Zürn C, Hartmann U, Wöhrle J, Nusser T, Dippon J, May AE, Gawaz M (2009) Catheter-based delivery of fluid paclitaxel for prevention of restenosis in native coronary artery lesions after stent implantation. Circ Cardiovasc Intervent 2:294–301CrossRef Herdeg C, Göhring-Frischholz K, Haase KK, Geisler T, Zürn C, Hartmann U, Wöhrle J, Nusser T, Dippon J, May AE, Gawaz M (2009) Catheter-based delivery of fluid paclitaxel for prevention of restenosis in native coronary artery lesions after stent implantation. Circ Cardiovasc Intervent 2:294–301CrossRef
Metadaten
Titel
Treatment of small coronary arteries with a paclitaxel-coated balloon catheter
verfasst von
Martin Unverdorben
Franz X. Kleber
Hubertus Heuer
Hans-Reiner Figulla
Christian Vallbracht
Matthias Leschke
Bodo Cremers
Stefan Hardt
Michael Buerke
Hanns Ackermann
Michael Boxberger
Ralf Degenhardt
Bruno Scheller
Publikationsdatum
01.03.2010
Verlag
Springer-Verlag
Erschienen in
Clinical Research in Cardiology / Ausgabe 3/2010
Print ISSN: 1861-0684
Elektronische ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-009-0101-6

Weitere Artikel der Ausgabe 3/2010

Clinical Research in Cardiology 3/2010 Zur Ausgabe

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.